Oramed Pharmaceuticals Inc. earnings per share and revenue
On Mar 25, 2026, ORMP reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of 0.00 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.
Looking ahead to Q2 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Capricor Therapeutics Inc
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.55
Actual
-$0.62
Surprise
-12.56%
Kestra Medical Technologies, Ltd. Common Stock
Report Date
Mar 17, 2026 For Q3 26
Estimate
-$0.60
Actual
-$0.61
Surprise
-0.39%
Sundial Growers Inc. Common Shares
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.01
Actual
$0.04
Surprise
+499.62%
High Tide Inc. Common Shares
Report Date
Mar 17, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+447.68%
Sanara MedTech Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.11
Actual
$0.04
Surprise
-64.35%
Cytosorbents Corp.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.09
Surprise
-76.47%
Nephros Inc.
Report Date
Mar 12, 2026 For Q4 25
Estimate
$0.01
Actual
$0.08
Surprise
+684.31%
FAQ
What were Oramed Pharmaceuticals Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Oramed Pharmaceuticals Inc. reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to Oramed Pharmaceuticals Inc.'s Q4 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Oramed Pharmaceuticals Inc. expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Oramed Pharmaceuticals Inc.'s next earnings report?
Based on --
analysts, Oramed Pharmaceuticals Inc. is expected to report EPS of -- and revenue of -- for Q2 2026.